R2 IP

About R2 IP

🎙️ The R² IP Podcast, hosted by Ray Miller, explores the intersection of law, science, and innovation. Ray is the US Chair of DLA Piper’s Life Sciences Patent Development & Strategy group and a trusted advisor to pharmaceutical, biotech, and technology companies. He has guided billion-dollar investments, extended patent exclusivity for portfolios valued at more than half a billion dollars, and built trade-secret programs strong enough to defeat high-stakes misappropriation claims. Each episode shows how intellectual capital—ideas, discoveries, and breakthroughs—can be transformed into intellectual property (IP) that protects, powers, and propels businesses forward. Ray’s work includes crafting regulatory exclusivity strategies where no composition-of-matter patents exist, securing freedom-to-operate for product launches, and navigating the International Trade Commission in complex infringement disputes—all experiences that bring a sharp, real-world perspective to every conversation. With a focus on life sciences, biotech, technology, and AI, the show delivers insights on patents, trade secrets, licensing, litigation, and strategy. Featuring thought leaders, investors, and innovators, the R² IP Podcast offers both practical guidance and strategic vision to entrepreneurs, executives, and professionals navigating today’s fast-moving innovation economy. ✨ What you’ll hear: •  How to turn cutting-edge research into enforceable IP assets •  Patent trends reshaping biotech, pharma, and emerging tech •  Strategies for protecting innovation in an AI-driven world •  Lessons from landmark cases and global IP developments •  Real-world insights from the frontlines of law, science, and business R² stands for “best fit”—and this podcast is the best fit for anyone looking to align IP strategy with business success. 📌 Recognitions & Thought Leadership •  Recognized by Chambers USA and The Legal 500 as a leading IP lawyer in licensing and patent strategy •  Named an Acritas Star and listed in Patent 1000 and Strategy 300 by International Asset Management •  Published widely on IP issues in outlets such as Bloomberg Law, Law360, IPWatchdog, and The Licensing Journal •  Frequent speaker at industry conferences and summits on protecting innovation, commercializing biotech breakthroughs, and aligning IP with investment strategy Reach out to Ray Miller at raymond.miller@us.dlapiper.com for inquiries or opportunities to join the conversation.

Publisher

Raymond Miller

Category

business · business

Language

en

Explicit

No

First episode

19 Aug 2025

Latest episode

1 Dec 2025

Latest episodes

7 episodes in the feed.

1. 

   1 Dec 2025

   Building a Biotech From Zero (Part 2 of 2): Investor Reality, Liquidity Myths & Founder Dynamics

   In Part 2, Ray and David continue their deep dive into the realities of early-stage biotech growth—moving into warrant coverage, investor upside, dilution, and the often-overlooked truth that early equity can be illiquid for years. David breaks down liquidation waterfalls, down rounds, fiduciary duties, and what happens when a company approaches insolvency. They close with a candid look at managing founder relationships, avoiding “dead equity,” and keeping the company aligned when the science, money, and people all collide. 01:43 Understanding Conversion Discounts 02:07 Negotiation Points and Valuation 03:11 Enterprise Value and Share Price 04:37 Impact on Founders' Equity 08:47 Capital Gains Tax Benefits 13:47 Liquidity and Exit Strategies 19:07 Investor Motivations and Risks 34:20 Board and Management Obligations 43:11 Ray's Retreat Overview

2. 

   26 Nov 2025

   Building a Biotech From Zero (Part 1 of 2): Formation, Founders & First Money In

   In Part 1 of this two-episode conversation, Ray sits down with longtime partner and life-sciences attorney David Smith to unpack the earliest—and most misunderstood—moments in forming a biotech company. They dive into choosing the right corporate structure, splitting founder equity, why timing matters, and how early financing tools like convertible notes and SAFEs really work. It’s a clear, practical look at the decisions that quietly determine whether a life sciences startup ever gets off the ground. It’s candid, practical, and full of the small details only 30 years of trenches-level experience can give you.

3. 

   5 Nov 2025

   Stacking Exclusivity: How Regulatory Incentives Power Drug Innovation

   A pharmacist–turned–regulatory strategist and a 25-year patent attorney walk into a podcast… and blow up the myth that “no composition of matter means no value.” Ray and Nicole break down how regulatory exclusivity actually drives drug innovation, often more powerfully than patents. Hear how NCE, orphan drug, pediatric, and GAIN Act exclusivity can turn an old or overlooked molecule into a fundable, defensible asset. Discover why biologics play by completely different rules, why there’s no Orange Book, and what the mysterious “patent dance” really is. Learn how exclusivities can stack (and when they absolutely don’t), including real examples of companies turning five years into ten—or more. Get a preview of skinny labeling, the loophole that stops perpetual exclusivity and deserves its own episode. Plus: a rapid tour of EU, China, and Japan exclusivity systems and how global rights shape investment strategy. A fast, clear, myth-busting guide to one of the most misunderstood forces in the life sciences industry.

4. 

   17 Sept 2025

   Untangling Double Patenting with Robert Matthews

   In this episode, Ray Miller welcomes longtime colleague and patent scholar Robert A. Matthews, Jr., author of the Annotated Patent Digest and one of the most respected voices in U.S. patent jurisprudence. Together, Ray and Bob dive deep into one of the thorniest doctrines in patent law: double patenting—both statutory and obviousness-type. They explore its roots in §101, how courts have shaped its modern application, and why it continues to frustrate practitioners and innovators alike. The discussion ranges from: The origins and evolution of double patenting doctrine. How obviousness-type double patenting (ODP) has become a frequent (and sometimes overused) tool by examiners. The impact of patent term adjustment (PTA) and patent term extension (PTE) on life sciences portfolios. Safe harbors under §121 and the importance of consonance. Practical strategies for navigating terminal disclaimers without giving away hard-fought patent term. Blending real-world strategy with academic perspective, this conversation offers a rare, behind-the-scenes look at how ODP disputes play out in prosecution, litigation, and policy. Whether you’re a litigator, prosecutor, or in-house counsel managing valuable life sciences IP, this episode provides sharp insights on how to safeguard term and preserve value.

5. 

   2 Sept 2025

   Radical Transparency or Regulatory Minefield? FDA’s CRL Data Dump Explained”

   On July 10, 2025, the FDA did something unprecedented: it dropped over 200 Complete Response Letters (CRLs) for public viewing—documents once considered trade secret goldmines. In this episode, host Ray Miller (Partner, DLA Piper) dives deep into what this massive disclosure means for biopharma innovators, IP strategists, and investors. Is this bold new transparency a regulatory revolution—or a compliance nightmare? We unpack: Why CRLs are so sensitive—and why their release matters The collision course between radical transparency and trade secret law What this means for patent filings, investor communications, and litigation exposure How AI is helping lawyers and companies mine this data for insights and avoid costly missteps The future of hybrid IP strategies in the post-CRL publication world Whether you're a GC, VC, scientist, or simply regulatory-curious, this episode explores the fine line between disclosure and disaster—and how you can turn this shake-up into strategic advantage. R² IP: Where legal nuance meets biotech strategy—with just enough humor to make it go down smooth. https://www.raysretreat.com/s/Rays-Retreat-2025-Think-Piece-on-Radical-Transparency-FDAs-Complete-Response-Letter-Release-Challeng.pdf Radical Transparency: FDA’s Complete Response Letter Release Challenges Trade Secret Norms  (https://www.raysretreat.com/s/Rays-Retreat-2025-Think-Piece-on-Radical-Transparency-FDAs-Complete-Response-Letter-Release-Challeng.pdf)

6. 

   27 Aug 2025

   One Plus One Equals Three: The Power of Patents + Trade Secrets

   In this second episode of the R² IP Podcast, host Ray Miller (https://www.dlapiper.com/en/people/m/miller-raymond) (Partner, DLA Piper) is joined once again by Nicole Endejann (https://www.dlapiper.com/en-us/people/e/endejann-nicole) (Partner, DLA Piper), returning as a recurring guest to explore the nuanced dance between patents and trade secrets in life sciences and tech. Is it patents or trade secrets? That binary thinking is out. The smartest companies are layering both—creating a force multiplier that delivers more than the sum of its parts. Together, Ray and Nicole dive into: Why small molecule innovators still rely on patents—but secretly win on process know-how How biologics shift the IP battlefield to cell lines, culture conditions, and purification secrets What digital health, AI models, and data platforms can teach us about protecting code and training sets The rise of hybrid IP strategies—designed for speed, flexibility, and long-term advantage Whether you’re patent-heavy, trade-secret-leaning, or somewhere in between, this episode offers fresh strategies and real-world examples to help you think smarter about your IP portfolio. R² IP: Translating Intellectual Capital into IP—with insight, wit, and recurring guests who know their stuff. DLA Piper (https://www.dlapiper.com/en)

7. 

   19 Aug 2025

   Compounding Pharmacy Podcast

   The R² IP Podcast dives into how ideas become IP — and how IP drives business success. Hosted by Ray Miller, each episode blends law, science, and strategy for innovators, entrepreneurs, and leaders shaping the future

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Apple Podcasts (US)

5.0 / 5

4 ratings

Contact R2 IP

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.